Page 69 - EJMO-9-2

Eurasian Journal of Medicine

and Oncology

REVIEW ARTICLE
Gut microbiota and hyperuricemia: From

mechanisms to therapeutic strategies

Xiaojie Lu , Yuetong Zhao , Shuang Wu , Yunze Xing , Yaxuan Fang ,
1,2
1,2
1,2
1,2
1,2
Haitao Xing , Ming Pei , Jie Li , Yanheng Qiao , Yongming Tian , and
1,2
1,2
1,2
1,2
1,2
Bo Yang *
1,2
1 Department of Nephrology, First Teaching Hospital of Tianjin University of Traditional Chinese
Medicine, Tianjin, China
2 Department of Nephrology, National Clinical Research Center for Chinese Medicine Acupuncture
and Moxibustion, Tianjin, China
Abstract
Hyperuricemia (HUA), a condition characterized by elevated levels of uric acid (UA)
in the bloodstream, is intricately connected to an imbalance in the gut microbiota.
UA, a byproduct of purine metabolism, serves as a crucial endogenous antioxidant.
Recent research indicates that modifying the gut microbiome offers a promising
avenue for managing HUA. This work delves into the complex relationship between
HUA and changes in the gut microbiota, examining its impact on UA excretion,
reabsorption, and the activity of enzymes involved in purine breakdown. Elucidating
the precise mechanisms behind this connection is essential for developing effective
treatments, and exploring various therapeutic approaches, including probiotics,
prebiotics, dietary interventions, and fecal microbiota transplantation, which
*Corresponding author: target the gut microbiota to reduce UA levels. These treatments may exert their
Bo Yang
(yb8203@126.com) effects through diverse pathways, such as inhibiting key enzymes, regulating UA
transporters, reducing oxidative stress and inflammation, and restoring the balance
Citation: Lu X, Zhao Y, Wu S, et al. of the gut microbiome. Furthermore, maintaining a healthy gut barrier is a valuable
Gut microbiota and hyperuricemia:
From mechanisms to therapeutic complementary therapy. This review aims to provide insights into the potential of gut
strategies. Eurasian J Med Oncol. microbiota manipulation as a novel and promising strategy for managing HUA. While
2025;9(2):61-77. this approach holds great promise, it is important to consider the potential risks and
doi: 10.36922/ejmo.8579
challenges associated with gut microbiota manipulation, and further research and
Received: January 17, 2025 clinical trials are warranted to fully understand its efficacy and safety.
Revised: February 16, 2025
Accepted: March 6, 2025 Keywords: Hyperuricemia; Intestinal flora; Uric acid metabolism; Probiotics; Nutritional
interventions
Published online: March 25, 2025
Copyright: © 2025 Author(s).
This is an Open-Access article
distributed under the terms of the
Creative Commons Attribution 1. Introduction
License, permitting distribution,
and reproduction in any medium, The prevalence of hyperuricemia (HUA), characterized by elevated serum uric acid (UA)
provided the original work is levels, has become a significant health concern, with implications for the development
properly cited. of gout, cardiovascular disease, and chronic kidney disease. HUA is multifactorial
Publisher’s Note: AccScience in origin, involving both genetic and environmental determinants. Genetic factors,
Publishing remains neutral with such as polymorphisms in the solute carrier family 2 member 9 (SLC2A9) and
regard to jurisdictional claims in
published maps and institutional glucose transporter-like protein-9 (GLUT9) genes, and reduced activity of the UA
affiliations. efflux transporter breast cancer resistance protein (BCRP)/ATP-binding cassette

Volume 9 Issue 2 (2025) 61 doi: 10.36922/ejmo.8579